SLC38A4-AS1: A Potential Drug Target and Biomarker (G100288798)

Target Name: SLC38A4-AS1

NCBI ID: G100288798

SLC38A4-AS1

Other Name(s): SLC38A4-AS1 variant 5 | SLC38A4 antisense RNA 1, transcript variant 5 | LOC100288798 | SLC38A4 antisense RNA 1

SLC38A4-AS1: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 38 (SLC38A4) is a protein that is expressed in the brain and is involved in the transport of glucose into the cell. It has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

SLC38A4 is a member of the SLC transmembrane protein family, which is characterized by the presence of a transmembrane protein that spans the cell membrane and is responsible for the delivery of various substances into or out of the cell. SLC38A4 is expressed in the brain and is involved in the transport of glucose into the cell, which is critical for the proper functioning of the brain.

Studies have suggested that SLC38A4 may be involved in the development and progression of various neurological and psychiatric disorders. For example, researchers have found that individuals with Alzheimer's disease have lower levels of SLC38A4 in their brain compared to healthy individuals. Additionally, studies have shown that individuals with depression have lower levels of SLC38A4 in their brain compared to healthy individuals.

In addition to its potential role in neurological and psychiatric disorders, SLC38A4 has also been identified as a potential biomarker for these disorders. Researchers have found that SLC38A4 levels can be used as a diagnostic marker for Alzheimer's disease, with lower SLC38A4 levels being associated with an increased risk of the disease.

Furthermore, SLC38A4 has also been shown to be involved in the regulation of cellular processes that are important for brain function. For example, studies have shown that SLC38A4 is involved in the regulation of the release of a neurotransmitter called glutamate, which is important for the functioning of the brain.

In conclusion, SLC38A4 is a protein that is expressed in the brain and is involved in the transport of glucose into the cell. Studies have suggested that SLC38A4 may be involved in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease and depression. Additionally, SLC38A4 has also been identified as a potential biomarker for these disorders. Further research is needed to fully understand the role of SLC38A4 in these conditions, as well as its potential as a drug target.

Protein Name: SLC38A4 Antisense RNA 1

The "SLC38A4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC38A4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets